Results 11 to 20 of about 337,805 (303)

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma

open access: yesJournal for ImmunoTherapy of Cancer, 2022
Background Camrelizumab and chemotherapy demonstrated durable antitumor activity with a manageable safety profile as first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC).
Jun Liu   +15 more
semanticscholar   +1 more source

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.

open access: yesJournal of the American Medical Association (JAMA), 2021
Importance Standard first-line therapy for advanced or metastatic esophageal carcinoma is chemotherapy, but the prognosis remains poor. Camrelizumab (an anti-programmed death receptor 1 [PD-1] antibody) showed antitumor activity in previously treated ...
Hui‐yan Luo   +29 more
semanticscholar   +1 more source

Fbxw8 protein promotes the proliferation and metastasis of ESCC [PDF]

open access: yesE3S Web of Conferences, 2020
Objective: This article plans to investigate Fbxw8 protein expression in esophageal squamous cell carcinoma tissues. And its effect on the proliferation ability of esophageal squamous cancer KYSE70 cells is analyzed.
Gao Shanshan, Zhao Dongdong
doaj   +1 more source

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma

open access: yesJournal for ImmunoTherapy of Cancer, 2022
Background Programmed cell death 1 (PD-1) blockade induces tumor regression in patients with advanced esophageal squamous cell carcinoma (ESCC); however, little is known about the efficacy of PD-1 blockade as neoadjuvant therapy in resectable ESCC.
Weixiong Yang   +22 more
semanticscholar   +1 more source

First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial

open access: yesNature Medicine, 2023
First-line systemic therapeutic options for advanced esophageal squamous cell carcinoma (ESCC) are limited. In this multicenter, double-blind phase 3 trial, a total of 551 patients with previously untreated, locally advanced or metastatic ESCC and PD-L1 ...
Yan Song   +23 more
semanticscholar   +1 more source

Diagnosis and Clinical Management of Esophageal Squamous Dysplasia [PDF]

open access: yesThe Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2021
Esophageal squamous cell carcinoma is the seventh most common cancer and the sixth most common cause of cancer death worldwide. Esophageal squamous dysplasia is the only histopathology that predicts the development of esophageal squamous cell carcinoma ...
Gwang Ha Kim
doaj   +1 more source

MicroRNAs and Esophageal Squamous Cell Carcinoma [PDF]

open access: yesDigestion, 2010
Esophageal cancer is a common cause of cancer death worldwide. Esophageal squamous cell carcinoma (ESCC) is the most predominant type. Certain microRNAs (miRNAs) function in tumorgenesis involved in important biological and pathologic processes. To reveal miRNAs’ signatures of ESCC, we analyzed miRNAs extracted from ESCC cell lines with the microRNA ...
Kayoko, Matsushima   +3 more
openaire   +2 more sources

Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma.

open access: yesCancer Research, 2023
Neoadjuvant chemoimmunotherapy (NACI) has shown promise in the treatment of resectable esophageal squamous cell carcinoma (ESCC). The microbiomes of patients can impact therapy response, and previous studies have demonstrated that intestinal microbiota ...
Hong Wu   +32 more
semanticscholar   +1 more source

Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma.

open access: yesCancer Cell, 2023
Neoadjuvant immune checkpoint blockade (ICB) demonstrates promise in operable esophageal squamous cell carcinoma (ESCC), but lacks available efficacy biomarkers.
Zhichao Liu   +19 more
semanticscholar   +1 more source

A novel pyroptosis scoring model was associated with the prognosis and immune microenvironment of esophageal squamous cell carcinoma

open access: yesFrontiers in Genetics, 2023
The phenotype of pyroptosis has been extensively studied in a variety of tumors, but the relationship between pyroptosis and esophageal squamous cell carcinoma (ESCC) remains unclear. Here, 22 pyroptosis genes were downloaded from the website of Gene Set
Zhan-Fei Zhang, Zhan-Fei Zhang
doaj   +1 more source

Home - About - Disclaimer - Privacy